CEO – Cann Group Limited, Chair – Medicinal Cannabis Industry Australia
Drawing on nearly three decades experience at global agribusiness Nufarm (ASX: NUF), and as the founding Chairman of MCIA, Cann Group’s CEO Peter Crock is shaping the future of the medicinal cannabis industry in Australia. With Peter at the helm and working closely with an experienced board of directors, Cann Group (ASX: CAN) received the first commercial cultivation licence in Australia, and was the first medicinal cannabis company to successfully list via an Initial Public Offering (IPO) on the Australian Securities Exchange (ASX), raising AUD$13.5 million.
To accelerate its growth, Cann Group has completed subsequent capital raisings totalling more than AUD$125m, which has enabled the advancement of its’ most ambitious project to date; a controlled environment, automated production facility which will be capable of producing up to 70,000kg of medicinal cannabis products per year when at full capacity.
With deep knowledge and experience in the areas of marketing, business and technology development, as well as mergers and acquisitions, Peter has overseen the growth and advancement of Cann Group.
In chairing the MCIA, Australia’s peak industry body for medicinal cannabis, Peter is well versed in the management of regulatory framework in both Australia, and abroad.
CEO & Executive Director Cronos Australia
Rodney Cocks is an Executive Director and Chief Executive Officer of Cronos Australia. Rodney is a Director of NewSouthern Capital, a private equity firm he co-founded which undertakes business in the real estate, cannabis and digital sectors. Prior to Cronos Australia, he was on the Senior Leadership Team at Linfox and was a Consultant at the Boston Consulting Group. Rodney also served on the Counter Narcotics Team of the British Embassy in Kabul, Afghanistan and with the United Nations in Afghanistan, Sri Lanka, Pakistan and Iraq. He started his career as an Infantry Officer in the Australian Army. Rodney holds a BComm from the University of Melbourne, LLB from the Queensland University of Technology, MBA from the Wharton School, University of Pennsylvania, MPA from the Harvard Kennedy School, Harvard University and is a Graduate of the Australian Institute of Company Directors and the Royal Military College, Duntroon. He is an admitted Lawyer to the Supreme Court of New South Wales and was also a Fellow at Harvard University and the 2005 Victorian Australian of the Year. In 2003 Rodney was awarded a Conspicuous Service Medal for his actions in the aftermath of the 2002 Bali bombings.
Executive Chairman & CEO MedReleaf Australia
Russell co-founded MedReleaf Australia with Nathan Davis in 2016 as a privately owned medicinal cannabis company.
He has 35 years success in pharmacy business ownership, management and innovation combined with experience in a number of other fields including pharmacy wholesaling to an 80 member group of pharmacist proprietors, property development, business mentoring, medical centre management and semi-professional sports coaching as an accredited AFLQ senior coach.
Elisabetta Faenza MAICD
CEO LeafCann Group
Elisabetta is an expert in relationship management, optimising individual, organisational and societal outcomes, facilitating collaboration and fundraising through win-win relationships. As Co-Founder and CEO of LeafCann Group, Elisabetta has driven the organisation’s strategic positioning as an industry leader. With her core team Elisabetta has expertly laid the groundwork for product development, acquiring critical infrastructure, and developing patenting, licensing and certification pathways. This has positioned LeafCann as a future operational centre of excellence for the emergent Medicinal Cannabis sector in Australasia and Europe.
Elisabetta is a Clinical Hypnotherapist and consultant hypnotherapist to medical and allied health practices including; pain management specialists, physiotherapists, and dentists. Elisabetta has extensive experience as a strategic planner and relationship manager for transnationals and NGOs in the health and regenerative agriculture sectors. Her experience in project planning, strategic partnerships and fundraising has allowed her to identify key strategic partners and negotiate joint venture agreements both nationally and internationally.
MA (Oxon) FCCA GAICD GCM
Nick is an accomplished leader in life sciences with over 25 years of experience in industry, equity research and investment banking. A proven record of driving commercial success and revenue growth. Extensive cross-functional expertise in finance, operations, strategy, business development, investor relations, M&A and capital raising. His previous roles include CEO of Proteolytics; Chief Business Officer of SUDA Pharmaceuticals (ASX:SUD); and Chief Financial Officer of PYC Therapeutics (ASX:PYC). Nick is a qualified accountant; a Graduate of the AICD; holds a Graduate Certificate in Management (with Distinction) from the AIB; and has a BA (Hons) and MA in Chemistry from Oxford University.
CEO and Managing Director, Epilepsy Action Australia
Carol’s extensive background spans more than 35 years in the not-for-profit human services sector. She has been at the forefront of the medical cannabis movement in Australia. In her role at Epilepsy Action she has had significant contact with people faced with managing very challenging forms of medication resistant epilepsy, with few or no conventional options left. Carol has seen the changes in people’s lives, including reduction in the severity and frequency of seizures, resulting from use of medicinal cannabis.